The Effect Of ApoE/SLCO1B1 Gene Polymorphism On The Application Of Rosuvastatin In Patients With Dyslipidemia

Objective With the rapid development of social economy and the improvement of people's living standards,atherosclerotic cardiovascular disease has become one of the most common diseases threatening human health.Numerous domestic and international studies have shown that dyslipidemia characterized by elevated LDL-C or TC is an important risk factor for atherosclerotic cardiovascular disease(ASCVD).Therefore,lipid-regulating therapy can reduce the incidence of cardiovascular diseases.Statins can effectively reduce lipid and significantly reduce the risk of cardiovascular events(including myocardial infarction,coronary heart disease death and ischemic stroke)in the primary and secondary prevention of ASCVD,and have become the most important drugs for the prevention and treatment of cardiovascular diseases.But it also had side effects,such as myopathy,abnormalities in liver enzymes,an increased risk of diabetes,and memory and cognitive impairment.Apolipoprotein E(ApoE)is a multifunctional protein composed of 299 amino acid residues encoded by the gene on chromosome 19.It is widely involved in the metabolism of the body and plays an important role in cholesterol transport and lipoprotein metabolism.ApoE has obvious polymorphism,which is one of the genetic factors leading to the difference of lipid and lipoprotein levels among individuals.OATP1B1(SLCO1B1)is mainly expressed in the basal lateral membrane of hepatocytes,and is crucial to liver uptake and clearance of various drug substrates and endogenous compounds.The polymorphism of SLCO1B1 has an important impact on the pharmacokinetics of statins,the risks of statins,and the efficacy of statins in the treatment of lipid-lowering stable plaques.The purpose of this study was to explore the correlation between ApoE/SLCO1B1 gene polymorphisms and the efficacy and safety of rosuvastatin in reducing fat from the perspective of pharmacodynamics.Methods The subjects were selected from Baotou Central Hospital from December 2017 to December 2018.All the selected patients wereexamined for ApoE and SLCO1B1 genotypes.The results of ApoE genotype were divided into E2/E2,E2/E3,E3/E3,E2/E4,E3/E4 and E4/E4 groups.SLCO1B1 521T>C genotype was divided into TT,TC and CC groups.SLCO1B1 388A>G genotype was divided into AA,AG and GG groups.After admission,rosuvastatin calcium 10mg/ was taken later,and was divided into different groups according to the course of treatment(1month group,3 months group,6 months group).Analysis of variance was used to explore the relationship between ApoE and SLCO1B1 521T>C / 388A>Ggene polymorphism in patients with dyslipidemia.Results(1)The polymorphism of ApoE gene was associated with the blood lipid levels in Chinese population,and the levels of LDL-C were lower for the alleles of ApoE 2 than for the E3/E3 genotypes.(2)The efficacy of rosuvastatin for the lowering of lipid was not satisfactory in patients with ApoE gene ?4 allele.(3)SLCO1B1 521 T>C gene polymorphism was associated with the incidence of myopathy caused by rosuvastatin,and CC genotype had a higher risk.Conclusion The polymorphism of ApoE and SLCO1B1 gene is related to the regulation of lipid and safety of rosuvastatin,which can guide the individualized clinical use of statin.